Atlas Trials

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Clinical trial NCT02586350 · COMPLETED

Trial details

NCT number
NCT02586350
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Medullary Thyroid Carcinoma
Start date
2015-07-01
Primary completion
2018-09-30
Enrollment
91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.